Cardiovascular disease risk is driven, per established AHA/ACC guidelines, primarily by two factors, ApoB and blood pressure, with hs-CRP adding a genuinely independent inflammatory risk signal on top, confirmed in the landmark JUPITER trial. This is a guideline-cited framework rather than an invented composite score, worth understanding as three distinct, complementary risk signals rather than one undifferentiated "heart health" number. The targets that follow from it: ApoB below 100 mg/dL at moderate risk, blood pressure below 120/80 mmHg, and hs-CRP below 1.0 mg/L.
- ApoB and blood pressure are established primary drivers of atherosclerotic risk (AHA/ACC guidelines).
- hs-CRP adds independent inflammatory risk information, confirmed in the JUPITER trial.
- ApoB counts actual particle number, a more direct measure than standard cholesterol.
- These three signals are complementary, not redundant, each reflects a distinct risk pathway.
Why ApoB and blood pressure are primary
ApoB counts the actual number of cholesterol-carrying particles in the blood, rather than the total cholesterol packed inside them. Current AHA/ACC guidance treats that as the more direct measure of atherosclerotic risk, because each particle can penetrate an artery wall and start plaque forming regardless of how much cholesterol it happens to carry.
Blood pressure is the force of blood against those artery walls. It is among the most extensively studied numbers in cardiovascular medicine, and it maps directly onto mechanical stress on the vessel over time.
Why hs-CRP adds an independent signal
The JUPITER trial showed that hs-CRP, a marker of low-grade systemic inflammation, adds independent cardiovascular risk information even after fully accounting for cholesterol. Inflammation contributes through a separate biological pathway rather than just tracking alongside lipids.
That is why hs-CRP is tracked as its own signal rather than folded into a single cholesterol-based score.
The risk factors, and what each actually contributes
Cardiovascular risk is usually presented as an undifferentiated list. The factors differ substantially in strength, in how directly they act, and in whether you can change them, and treating them as equivalent leads people to optimize the wrong ones.
INTERHEART, covering 52 countries, found that a small number of modifiable factors account for the large majority of first myocardial infarction risk. The sorting below is by causality and modifiability rather than by share of risk, but the shape of that finding is why the list is short.
Causal and modifiable
- ApoB / atherogenic particle count. The most direct causal driver. Every particle carrying cholesterol into the artery wall has one ApoB molecule, so counting them measures the actual insult better than measuring the cholesterol they carry. Mendelian randomisation studies, which use genetic variation to approximate a lifelong randomised trial, support causality rather than mere association.
- Blood pressure. Causal through direct mechanical injury to the endothelium. Cumulative midlife exposure predicts far better than any single reading.
- Smoking. Causal through endothelial damage, oxidation and thrombosis. The effect on risk falls quickly after cessation, faster than most other factors.
- Insulin resistance and diabetes. Causal through glycation, endothelial dysfunction and an unfavourable lipid pattern. Often present years before diagnosis, which is why fasting insulin is worth measuring.
Causal but not modifiable
- Lipoprotein(a). Largely genetically determined, unaffected by diet or exercise, and elevated in roughly one in five people. Worth testing once, because a high result raises the value of controlling everything else rather than being actionable itself.
- Age, sex and family history. Unmodifiable, and they shift the threshold at which intervening on the modifiable factors becomes worthwhile.
Risk markers rather than causes
- hs-CRP. Adds independent predictive information, most convincingly demonstrated in the JUPITER trial, without being a target you treat directly. It reflects the inflammatory environment in which plaque develops.
- Triglycerides and HDL. Strongly associated, but trials raising HDL pharmacologically haven’t reduced events, which is the clearest available demonstration that association isn’t causation in this domain.
The practical consequence is a hierarchy rather than a checklist. Getting ApoB and blood pressure right addresses the two strongest causal levers. Chasing HDL upward with supplements addresses a marker that moves with health without carrying it.
Which markers to measure, and their targets
This list gives measurement targets for the factors sorted above, including the markers worth tracking without being treatment targets.
Cardiovascular risk assessment has moved a long way from a total cholesterol reading. The markers below are ordered by how directly each maps onto the underlying disease process.
- ApoB. One molecule per atherogenic particle, so it counts the particles attempting to enter the artery wall. Below 100 mg/dL is a reasonable general target; below 80 is optimized; below 65 is aggressive and typical of secondary prevention.
- Lp(a). Largely genetically determined, stable across life, and unaffected by diet or exercise. Elevated in roughly one in five people. Worth measuring once, because a high result changes how aggressively everything else is worth treating, even though the value itself won’t move.
- Blood pressure. Cumulative exposure matters more than any reading. Below 120/80 is the target, and home measurement over several days beats a single clinic reading.
- hs-CRP. Adds risk information independent of lipids, which is what the JUPITER trial demonstrated. Below 1.0 mg/L is low risk.
- Coronary artery calcium score. A CT scan quantifying calcified plaque. A score of zero in a middle-aged adult is strongly reassuring; a score above 100 substantially reclassifies risk upward. It measures accumulated disease rather than predicting future risk from proxies, which is why it can settle borderline cases.
Why risk calculators and markers disagree
Population risk calculators weight age heavily, because age is the strongest predictor at population level. That makes them poor at identifying a 40-year-old with substantial early disease, since the arithmetic keeps their ten-year risk low regardless of their ApoB. Someone with a genuinely concerning lipid profile can be told their ten-year risk is under five percent, which is true and beside the point when the disease develops over forty years rather than ten.
The lifetime framing
Because atherosclerosis accumulates from early adulthood, the relevant quantity is exposure integrated across decades, not a level on one day. Modest lowering starting at 35 outperforms aggressive lowering starting at 60 in modeling studies, for the same reason a small leak matters more over years than a large one over months.
This is also why lifestyle and medication aren’t competing options. Diet, weight and exercise move ApoB meaningfully but often not enough on their own for someone starting high, and the gap between what lifestyle achieves and where the target sits is exactly the conversation to have with a doctor.
The risk factors, side by side
| Marker | What It Reflects | Evidence Basis |
|---|---|---|
| ApoB | Actual atherogenic particle count | AHA/ACC guidelines |
| Blood pressure | Mechanical vascular stress | Extensively established, decades of research |
| hs-CRP | Reports the inflammatory environment in which plaque develops, rather than contributing to it causally | JUPITER trial |
How to track the risk factors together
Generic heart-health content collapses cardiovascular risk into a vague “cholesterol is bad” message, which misses the more precise three-driver framework the guidelines actually use.
Track ApoB, blood pressure and hs-CRP together rather than any one in isolation, because they reflect distinct and complementary risk pathways. A good number on one says little about the other two.
They also respond at different speeds. Blood pressure moves relatively quickly, ApoB responds to sustained exercise and dietary change more gradually, and hs-CRP follows the same broad lifestyle levers.
Longevity Coach IQ tracks all three drivers together, rather than reducing cardiovascular risk to one number.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation, 2019;139(25):e1082-e1143. The guideline framework referenced throughout. DOI
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine, 2008;359(21):2195-2207. The independent inflammatory signal from hs-CRP. DOI
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic and clinical studies: a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2017;38(32):2459-2472. The basis for cumulative lifetime exposure mattering more than any single reading. DOI
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2020;41(1):111-188. The European position, which sets ApoB targets directly. DOI
- Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART). The Lancet, 2004;364(9438):937-952. The basis for ranking modifiable risk factors by contribution. DOI
Frequently asked
What are the primary drivers of cardiovascular risk?
ApoB and blood pressure per AHA/ACC guidelines, plus an independent inflammatory signal from hs-CRP (JUPITER trial). hs-CRP adds independent predictive information as a marker of the inflammatory environment rather than as a causal driver: genetic variants that raise CRP do not raise cardiovascular risk, while genetic variation reducing IL-6 signalling does lower it.
Why is ApoB more direct than standard cholesterol?
It counts actual atherogenic particle number, rather than just total cholesterol content.
Does hs-CRP add information beyond cholesterol?
Yes, the JUPITER trial showed independent risk information even after accounting for cholesterol.
What is a good ApoB level?
Lower is better, and the target depends on your overall risk rather than being one universal number. Someone with existing cardiovascular disease is generally aimed at a considerably lower figure than someone at low baseline risk.
Is high cholesterol always bad?
The total cholesterol number on its own is a poor guide, which is why it has been progressively de-emphasized. The number of atherogenic particles, captured by ApoB, tracks risk more directly than the amount of cholesterol they carry.
How can I lower my ApoB?
Reducing saturated fat, losing excess weight, increasing fiber and regular exercise all help. For many people at meaningful risk, diet and exercise alone don’t achieve target levels, which is where medication becomes a discussion with a doctor.
Does family history of heart disease matter?
Substantially. It’s also worth knowing that Lp(a), a largely genetically determined risk factor, runs in families and isn’t affected by lifestyle, which explains some otherwise puzzling family patterns.
Should I get my Lp(a) tested?
It’s increasingly suggested as a once-in-a-lifetime test, since levels are largely genetic and stable. Knowing it doesn’t change lifestyle advice, but it changes how aggressively other modifiable risks are worth treating.